Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage
2025
Abbo, Sandra R. | Yan, Kexin | Geertsema, Corinne | Hick, Tessy A.H. | Altenburg, Jort J. | Nowee, Gwen | van Toor, Chris | van Lent, Jan W. | Nakayama, Eri | Tang, Bing | Metz, Stefan W. | Bhowmik, Ryan | de Silva, Aravinda M. | Prow, Natalie A. | Correia, Ricardo | Alves, Paula M. | Roldão, António | Martens, Dirk E. | van Oers, Monique M. | Suhrbier, Andreas | Pijlman, Gorben P.
Zika virus (ZIKV) caused unprecedented outbreaks in South America and the Caribbean in 2015–2016, leading primarily to a series of abnormalities in neonates termed congenital Zika syndrome. The threat of ZIKV reemergence has seen the development of multiple ZIKV vaccines that are at the preclinical stage or in early-stage clinical trials. Herein, we describe a pathway to the development of ZIKV vaccines generated using a baculovirus-insect cell expression system, which is widely applied for the manufacture of biologics for human use. Virus-like particle (VLP) vaccines comprising CprME and subviral particle (SVP) vaccines comprising prME were evaluated for their ability to mediate protection against ZIKV challenge in Ifnar1−/− mice. Initial attempts resulted in VLP and SVP vaccines that failed to present quaternary epitopes and did not provide effective protection. To improve the SVP vaccine, two modifications were introduced: firstly, an alanine to cysteine substitution (A264C) in the E domain II region to promote the formation of stabilized E homodimers and, secondly, the use of Spodoptera frugiperda Sf9 insect cells that had been adapted to grow and produce vaccine at a neutral pH of 7. E homodimers largely retain their pre-fusion conformation at pH 7, which is a requirement for the induction of effective neutralizing antibody responses. The stabilized SVP-A26C vaccine induced high levels of neutralizing antibodies and protected male Ifnar1−/− mice against viremia and testicular damage. Our study reiterates the need to present the immune system with E dimers arranged in authentic quaternary conformations and provides a scalable production method for this novel ZIKV vaccine.
显示更多 [+] 显示较少 [-]